Media.Player

Ligands for Alpha-4-Beta-1 Integrin

详细技术说明

Highly potent ligands for activated alpha-4 beta-1 integrin have been identified by University of California, Davis researchers. These ligands can potentially be used as targeting agents for cancer as well as anti-inflammatory agents for autoimmune diseases. Notable applications of these alpha-4 beta-1 ligands include: Targeting therapy for imaging of cancers including lymphoid malignancies, which have high level of activated alpha-4 beta-1 integrin on the cell surface; Therapeutic uses as anti-inflammatory agents for autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and lupus; and, Treatment of both human and dog diseases listed above. The compounds for activated alpha-4 beta-1 integrin of the present invention have high affinity to human malignant lymphoid cells (both T- and B-cells, and including fresh malignant cells from patients with acute lymphocytic leukemia). Importantly, the binding affinities of these ligands are much higher than products currently developed.

*Abstract

Alpha-4 beta-1 ligands as targeting agents for cancer and autoimmune diseases

*IP Issue Date

Aug 18, 2009

*Principal Investigation

Name: Kit Lam

Department:

Name: Ruiwu Liu

Department:

Name: Li Peng

Department:

附加资料

Patent Number: US7576175B2
Application Number: US2005140548A
Inventor: Lam, Kit S. | Liu, Ruiwu | Peng, Li
Priority Date: 27 May 2004
Priority Number: US7576175B2
Application Date: 26 May 2005
Publication Date: 18 Aug 2009
IPC Current: C07K000508 | A61K004506 | C07C027542 | C07K000502 | C07K000510 | C07K000702 | C07K000704 | C07K000708 | C07K001400 | H02N000100 | A61K003806 | A61K003807 | A61K003808 | A61K003810 | A61K003816 | C07K000100 | C07K0001107
US Class: 530331 | 530326 | 530327 | 530328 | 530329 | 530330 | 530333 | 530345 | 514013 | 514014 | 514015 | 514016 | 514017 | 514018
Assignee Applicant: The Regents of the University of California
Title: Alpha-4 beta-1 integrin ligands for imaging and therapy
Usefulness: Alpha-4 beta-1 integrin ligands for imaging and therapy
Summary: The ligand is used for treating cancer and an inflammatory or autoimmune disease in a subject. It is used for imaging a tumor, organ, or tissue. The cancer is a lymphoma or leukemia from non-Hodgkin's lymphoma, Hodgkin's lymphoma, B-cell lymphoma, Burkitt's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, T-cell lymphoma, multiple myeloma, hairy cell leukemia, or other cancers expressing α 4 β 1 -integrin. The inflammatory disease is inflammatory bowel disease, rheumatoid disease, fibrositis, pelvic inflammatory disease, acne, psoriasis, actinomycosis, dysentery, biliary cirrhosis, Lyme disease, heat rash, Stevens-Johnson syndrome, mumps, pemphigus vulgaris, asthma, or balstomycosis. The autoimmune disease is Type I diabetes mellitus, myasthenia gravis, vitiligo, Grave's disease, Hashimoto's disease, Addison's disease, autoimmune gastritis, autoimmune hepatitis, systemic lupus erythematosus, progressive systemic sclerosis and variants, polymyositis, dermatomyositis, pernicious anemia, primary biliary cirrhosis, autoimmune thrombocytopenia, Sjogren's syndrome, or multiple sclerosis (claimed).
Novelty: New alpha-4 beta-1 integrin ligand for treating cancer and inflammatory or autoimmune diseases e.g. inflammatory bowel disease in subject

主要类别

诊断/治疗

细分类别

癌症/肿瘤

申请号码

7576175

其他

Related Materials

Peng L, Liu R, Marik J, Wang X, Takada Y and Lam KS. 2006. "Combinatorial chemistry identifies high-affinity peptidomimetics against alpha(4)beta(1) integrin for in vivo tumor imaging." Nat Chem Biol. 2(7):381-9.
UC DAVIS RESEARCHERS REPORT NEW MOLECULE THAT TARGETS LEUKEMIA AND LYMPHOMA CELLS

Related Technologies

• Method for Regulating Apoptosis

Additional Technologies by these Inventors

• Three-Dimensional Cell Adhesion Matrix
• A Novel RGD-Containing Cyclic Peptide for use in Cancer Imaging and as a Targeted-Therapy Ligand
• Functional Illumination in Living Cells
• Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
• Nanoporphyrin Nanoparticles for Combination Phototherapy and Drug Delivery to Infantile Hemangiomas
• Early Detection of Ovarian Cancer Using Markers to Short Chain Carbohydrates
• PVA Nanocarrier System for Controlled Drug Delivery
• Site-Specific Ligation and Compound Conjugation to Existing Antibodies
• Novel Solid Tumor Chemodrug LLS2
• High Throughput Label-Free One-Bead-One-Compound (OBOC) Screening Assay
• Ligands for Improved Angiogenesis and Endothelialization of Blood Contacting Devices
• Proteoglycan Mimetics For Enhanced Wound Healing Angiogenesis And Vascular Repair

Tech ID/UC Case

11318/2004-325-0

Related Cases

2004-325-0, 2007-154-1, 2007-154-2

国家/地区

美国